Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228137 | 0.87 | KDR (0.60) | KDRCYP3A4EGFRKCNH2 | |
| SCHEMBL1227705 | 0.85 | KDR (0.59) | KDRCYP3A4EGFR | |
| SCHEMBL4373829 | 0.78 | EGFR (0.67) | KDREGFRKCNH2EPHA2EPHB4 | |
| Hydrochloric Acid SCHEMBL4373692 | 0.78 | EGFR (0.66) | KDREGFRKCNH2EPHA2EPHB4 | |
| SCHEMBL4374222 | 0.75 | KDR (0.70) | KDREGFREPHA2EPHB4 | |
| SCHEMBL4378628 | 0.74 | KDR (0.70) | KDREGFREPHA2EPHB4 | |
| SCHEMBL1227756 | 0.73 | KDR (1.00) | KDRCYP3A4EGFRKCNH2EPHB4 | |
| SCHEMBL4380962 | 0.73 | EGFR (0.64) | KDREGFR | |
| SCHEMBL1226468 | 0.72 | KDR (0.55) | KDRCYP3A4KCNH2 | |
| SCHEMBL1227536 | 0.72 | KDR (0.55) | KDRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280012-A2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7820814-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-7521450-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050124621-A1 | Novel inhibitors of kinases | BHIDE RAJEEV S (US) | 2005-06-09 | — | — | US | disclosed |
| US-6869952-B2 | Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | FGFR1, FLT1, FLT4 | KDR 6/4885CYP3A4 683/4885KMT2A 3232/4885 |
| US-20050124621-A1 | Novel inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885CYP3A4 3014/4885KMT2A 3513/4885 |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | FGFR1, FLT1, FGFR2 | KDR 9/4885CYP3A4 2215/4885KMT2A 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.